Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Winning Ugly and Failing Gracefully | Main | Sloppy Science »

March 29, 2012

Pfizer: Making the Case for a Breakup

Email This Entry

Posted by Derek

I would not like to count the number of times I've said bad things here about pharma mergers. The best of them, as far as I can see, have been not all that harmful, and the worst have been near-disasters. As the undisputed M&A kings of the industry over the last twenty years, I've been especially hard on Pfizer.

And now that great big financial wheel is turning. Huge mergers and acquisitions appear, finally, to be going out of favor. Since there are no longer reputations to be made, bold visions to be realized, and (don't forget) massive fees to be earned by implementing such moves, the latest word is: breaking up. Spinning off. Leaner, meaner, core businesses, unlocking value, more focus, back to what they do best . .you can write the Wall Street reports as well as I can. Goldman Sachs is out this week making the breathless case for Pfizer doing just this.

I suspect we're in for years of this sort of thing, with Abbott's spinoff of their pharma business now looks like the starter's pistol going off. (They named the new company AbbVie, which I hope they didn't pay someone too much to think up, the same time disappointing the legions of fans who wanted to see it named Costello). Get ready for a long cycle of devolution.

Comments (26) + TrackBacks (0) | Category: Business and Markets


COMMENTS

1. schinderhannes on March 29, 2012 7:08 AM writes...

Hi Derek,

the really sad thing about this is that Goldman Sachs and friends couldĀ“t care less if the do a merger or a split up they make money on it. I was always susspicious of the fact that only the financial wolrd has any benefit from M&As. And they lured us into believing this was to the greater good of pharma industry.
Unfortunately our managers were gullible enough....

Permalink to Comment

2. Over-paid chemist on March 29, 2012 7:16 AM writes...

Pfizer is selling Nutritionals and Animal Health so that it can raise funds to pay for the next acquisition.

Get on with the program.

Permalink to Comment

3. MQD on March 29, 2012 7:26 AM writes...

"Get ready for a long cycle of devolution."

Oh No! It's Devo!

Permalink to Comment

4. processchemist on March 29, 2012 7:28 AM writes...

Value maximization is probably the most destructive philosophy (or buzzword or excuse) in the last 50 years of history.

Permalink to Comment

5. Rick Wobbe on March 29, 2012 7:48 AM writes...

processchemist, #4, More specifically, the problem has arisen from the fact that the sole definition of "value" is shareholder return". We'd be far better off if our economic definition of "value" included things like meeting patient needs and innovating.

Permalink to Comment

6. HelicalZz on March 29, 2012 7:50 AM writes...

Value is always a relative thing. Breaking up Pfizer may well benefit investors in the short term, or over the next couple of years. But what gives Pfizer the best chance of succeeding for decades? Is it split up 'focused' companies some of which will succumb to competition and pressure, or a mix of businesses that should generate cash flows to the parent for the long term?

GS clearly favors the former, and I'm sure many investors do to (and add 'new' management with option rich compensation packages), but long term investors and dividend focused income investors should favor the perennially undervalued conglomerate for its ability to provide income with a decent yield. But these latter investors seem to be more and more the minority.

Shame about that.

Zz

Permalink to Comment

7. M on March 29, 2012 7:56 AM writes...

Rubin was the same person in who in just 2009 was beating the drum for PFE diversification and big take over - now, just 3 years on she is shouting about unlocking the value within PFE. Around 2015 she will again be bleating diversification/big take over. It's all to keep the M&A bankers busy and financing share-buybacks. Who gets screwed in all of this? Pharma employees - mainly scientists. Don't get sucked in to the evil of Wall St.

Permalink to Comment

8. Anonymous on March 29, 2012 8:13 AM writes...

"Oh No! It's Devo!"

We are not men. We are MBAs.


Permalink to Comment

9. johnnyboy on March 29, 2012 8:13 AM writes...

"Oh No! It's Devo!"

We are not men. We are MBAs.


Permalink to Comment

10. anon the II on March 29, 2012 8:34 AM writes...

@ schinderhannes

Although I agree with the sentiment of what you're saying, I don't think that the decision makers were gullible. If you looked at some of the departing packages the top guys got, "bought off" describes it better.

Permalink to Comment

11. schinderhannes on March 29, 2012 8:48 AM writes...

@ anon the II

point well taken!

Permalink to Comment

12. josh on March 29, 2012 8:50 AM writes...

"...disappointing the legions of fans who wanted to see it named Costello."

I see what you did there. Witty

Permalink to Comment

13. AbbVie is for Me on March 29, 2012 8:59 AM writes...

Abbott's success was always considered to come from it's diversification, different units performing well together to insulate each other from the ups and downs of the market. It was a core strength until one day they decided it wasn't.

Humira was lauded for its strong performance as the 'pipeline in a drug', its strong sales that brought in a lot of revenue for the company. Now, even with increasing sales, it's considered a liability for a variety of reasons. It was explained that too much of Abbott's profit came from Humira, around 20%. So, what do they do, they spin of the pharma side where its revenue will be closer to 50% of the new company, and right at the point where several things are going off-patent. The first couple of years at AbbVie (the most ridiculous name in the industry, by the way. Thanks, Miles!) are going to be tough, assuming they aren't already being shopped. They even kept the branded generics within Abbott rather than being part of the pharma company, as many feel it should have.

The only thing Abbott wanted to unlock was the door so they could push off something they no longer felt was going to benefit them over the next few lean years. Well, they also wanted to unlock the bank vault for upper management as well.

If the name AbbVie is any indication at their ability to make good decisions, well...

Permalink to Comment

14. Gilbert Pinfold on March 29, 2012 9:01 AM writes...

@ josh

GSK troll!

Permalink to Comment

15. josh on March 29, 2012 9:37 AM writes...

@Gilbert Pinfold

i am going to assume you were told to say that by the voices from your LIDA

Permalink to Comment

16. Derek Lowe on March 29, 2012 10:13 AM writes...

If there's a blog about Evelyn Waugh novels out there, I'll bet that they don't make jokes about drug discovery in the comments.

Permalink to Comment

17. NH_chem on March 29, 2012 11:05 AM writes...

I can say that I thought I was the only scientist that listened still to Devo. That is refreshing to see more out there.

As for Pfizer and a potential break-up, it is all driven by the stock price which is why a private company may be a better bet when looking at stability since they tend to be more patient.

Dividing Pfizer actually may be better for all.

Permalink to Comment

18. Bemused on March 29, 2012 1:47 PM writes...

Eh? Cost savings when you merge AND cost savings when you break up? If there's a management consultant out there, please enlighten us how that works...

Permalink to Comment

19. sgcox on March 29, 2012 7:00 PM writes...

18~Bemused:
It is very trivial. You merge, get some assets and fire people. + in money books. You break up => get read of marginal business and useless people. + in money books.
"firing people is just like printing your own money" - sorry, have no quotation source.

Permalink to Comment

20. JG on March 29, 2012 9:49 PM writes...

I'm trying to figure out enough about pharmaceuticals to write a book about the adventures therein. Ow! and Thanks!

I agree with the consensus that AbbVie has to be the craziest name they could have invented.

Permalink to Comment

21. drug_hunter on March 30, 2012 1:53 AM writes...

Could have called it AbbyNormal....

Permalink to Comment

22. CMCguy on March 30, 2012 12:47 PM writes...

@21- thanks for the LOL as immediately Young Frankenstein came to mind - you may want to see if you can Trademark that (or AbbVieNormal) as could be they will want to use as name of their first product?

Permalink to Comment

23. Sili on March 30, 2012 6:45 PM writes...

AbbVie en rose.

Good names never happen. Al Gore didn't name his investment firm Blood and Gore either.

Permalink to Comment

24. pilotgrrl on March 30, 2012 7:17 PM writes...

@NH_chem

Something for everyone!

Permalink to Comment

25. Jocko Homo on April 1, 2012 12:13 PM writes...

8. Anonymous
The Devo analogy is inspired - see Wikipedia:

"The name "Devo" comes "from their concept of 'de-evolution' - the idea that instead of continuing to evolve, mankind has actually begun to regress, as evidenced by the dysfunction and herd mentality of American society."

!

Permalink to Comment

26. Bruce Grant on April 2, 2012 10:50 AM writes...

Dr. Frederick Frankenstein: [to Igor] Now that brain that you gave me. Was it Hans Delbruck's?

Igor: [pause, then] No.

Dr. Frederick Frankenstein: Ah! Very good. Would you mind telling me whose brain I DID put in?

Igor: Then you won't be angry?

Dr. Frederick Frankenstein: I will NOT be angry.

Igor: Abby someone.

Dr. Frederick Frankenstein: [pause, then] Abby someone. Abby who?

Igor: Abby... Normal.

Dr. Frederick Frankenstein: [pause, then] Abby Normal?

Igor: I'm almost sure that was the name.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Molecular Printing of Drug Molecules. Say What?
Pfizer Walks Again By Night
Gitcher SF5 Groups Right Here
Changing A Broken Science System
One and Done
The Latest Protein-Protein Compounds
Professor Fukuyama's Solvent Peaks
Novartis Gets Out of RNAi